Archived AES Symposia 2005
Spanish Symposium - New Antiepileptic Drugs: What Have We Learned?
Program Length: 2 hrs 3 min
Since the introduction of second generation AEDs, much information has become available regarding their efficacy in selected populations and their immediate and long-term side effects. Guidelines for the use of new AEDs have recently been published by the AAN. New data has also emerged on the adverse effects of traditional AEDs, in particular effects on bone health and gender-specific risks. This symposium will address the selection of antiepileptic drugs in children and adults in light of the emerging information. Clinicians should understand the considerations that influence drug selection in new onset and refractory epilepsy. These include particular epilepsy syndromes, age and gender-related factors, drug pharmacokinetics, coexisting diseases, polypharmacy and drug interactions. There will be ample opportunity for participation and discussion of special considerations regarding issues that may be specific to different Spanish-speaking countries.
At the conclusion of this activity, participants should be able to:
- Formulate a rational approach to the selection of AEDs in children and adults with new onset epilepsy
- Formulate a rational approach to the selection of AEDs in children and adults with epilepsy refractory to traditional AEDs
- Recognize the potential adverse effects of antiepileptic drugs, including age- and sex-related effects, teratogenicity and effects on bone health
- Identify the limitations of the AAN guidelines for the use of new AEDs, and the application issues particular to Latin American countries.
Neurologists and other healthcare professionals involved in the care of children and adults with epilepsy. The program will be presented in Spanish, thus facilitating comprehension and enhancing participation of meeting attendees from Spanish-speaking countries.
Chair: Vicente J. Iragui, M.D., Ph.D.
Why Is the Cost of Epilepsy Care Different in Latin America and the USA?
Manuel Campos, M.D.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Manual Campos, M.D. has indicated he has no real or apparent conflicts of interest to report.
Vicente J. Iragui, M.D., Ph.D. has disclosed he has received consulting fees from UCB Pharma, Inc. and fees for non-CME services from Abbott Laboratories and Novartis.
Carlos Medina-Malo, M.D. has indicated he has no real or apparent conflicts of interest to report.
Samuel Wiebe, M.D. has indicated he has no real or apparent conflicts of interest to report.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.